Fig. 8
Downregulation of raft-phospho-PHBY259 reduces tumorigenic ability and sensitizes tumors to carboplatin treatment. a SKOV3GL-G4 cells were transfected with empty vector or mutant PHB plasmid (pD-PHBY259F-HA) for 48 h. After transfection, cells were cultured in CSC medium for 12 days. After 12 days, 1000 or 500 cells in 50 μl DPBS were mixed with 50 μl Matrigel and subcutaneously injected into the flanks of nude mice. In vivo CSC properties were determined by luciferase signal at week 4 post injection (mean ± SD; n = 5 per group; **, P < 0.01; *, P < 0.05, t test). b SKOV3GL-G4 cells were transfected with empty vector or pD-PHBY259F-HA for 48 h. After transfection, 2 × 106 cells in 50 μl DPBS were mixed with 50 μl Matrigel and subcutaneously injected into flanks of nude mice. Treatment with carboplatin (CBP) began 1 week after injection. Representative tumor images excised from mice at the end of the experiment at day 31. c Tumor growth kinetics were measured every 3 days after carboplatin (CBP) treatment. d, e Endpoints of tumor volume and tumor weight were measured (mean ± SD; n = 5 per group; **, P < 0.01; *, P < 0.05, t test)